Skip to main content
Premium Trial:

Request an Annual Quote

USPTO to Re-examine ExonHit Patent

NEW YORK (GenomeWeb News) – Jivan Biologics said yesterday that the US Patent and Trademark Office will re-examine a patent held by Paris-based ExonHit Therapeutics covering methods for identifying differentially spliced gene products.
 
The patent, No. 6,881,571, is at the center of a patent infringement suit filed last year by ExonHit against Larkspur, Calif.-based Jivan.
 
Earlier this year, Jivan requested a re-examination of all the claims in the patent on the basis of prior art that it believes was not considered during the original patent examination.
 
“We expect the patent office to consider whether claims in the ‘571 patent should be amended or invalidated in their entirety,” Jivan CEO Subha Srinivasan said in a statement.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.